Immunogenicity and Safety of Primary and Booster Vaccination With DTPa-HBV-IPV/Hib Vaccine

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2009
This study will assess the immunogenicity, safety and reactogenicity of GSK Biological\'s DTPa-HBV-IPV/ Hib vaccine as compared to GSK\'s DTPa-IPV/Hib vaccine co-administered with HBV according to a three-dose immunisation course and as a booster dose in infants born to hepatitis B antigen seronegative mothers and previously primed with a birth dose of GSK\'s HBV vaccine.
Epistemonikos ID: 517e419dc57fbfec710882a2107bc254ccb27893
First added on: Nov 24, 2021